Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

362 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Diagnosis, prevention, and management of bleeding episodes in Philadelphia-negative myeloproliferative neoplasms: recommendations by the Hemostasis Working Party of the German Society of Hematology and Medical Oncology (DGHO) and the Society of Thrombosis and Hemostasis Research (GTH).
Appelmann I, Kreher S, Parmentier S, Wolf HH, Bisping G, Kirschner M, Bergmann F, Schilling K, Brümmendorf TH, Petrides PE, Tiede A, Matzdorff A, Griesshammer M, Riess H, Koschmieder S. Appelmann I, et al. Among authors: brummendorf th. Ann Hematol. 2016 Apr;95(5):707-18. doi: 10.1007/s00277-016-2621-2. Epub 2016 Feb 26. Ann Hematol. 2016. PMID: 26916570 Review.
Epimutations mimic genomic mutations of DNMT3A in acute myeloid leukemia.
Jost E, Lin Q, Weidner CI, Wilop S, Hoffmann M, Walenda T, Schemionek M, Herrmann O, Zenke M, Brümmendorf TH, Koschmieder S, Wagner W. Jost E, et al. Among authors: brummendorf th. Leukemia. 2014 Jun;28(6):1227-34. doi: 10.1038/leu.2013.362. Epub 2013 Nov 27. Leukemia. 2014. PMID: 24280869 Free PMC article.
Bosutinib: a novel second-generation tyrosine kinase inhibitor.
Isfort S, Keller-v Amsberg G, Schafhausen P, Koschmieder S, Brümmendorf TH. Isfort S, et al. Among authors: brummendorf th. Recent Results Cancer Res. 2014;201:81-97. doi: 10.1007/978-3-642-54490-3_4. Recent Results Cancer Res. 2014. PMID: 24756786 Review.
Activated fibronectin-secretory phenotype of mesenchymal stromal cells in pre-fibrotic myeloproliferative neoplasms.
Schneider RK, Ziegler S, Leisten I, Ferreira MS, Schumacher A, Rath B, Fahrenkamp D, Müller-Newen G, Crysandt M, Wilop S, Jost E, Koschmieder S, Knüchel R, Brümmendorf TH, Ziegler P. Schneider RK, et al. Among authors: brummendorf th. J Hematol Oncol. 2014 Dec 14;7:92. doi: 10.1186/s13045-014-0092-2. J Hematol Oncol. 2014. PMID: 25498831 Free PMC article.
JAK Inhibition Impairs NK Cell Function in Myeloproliferative Neoplasms.
Schönberg K, Rudolph J, Vonnahme M, Parampalli Yajnanarayana S, Cornez I, Hejazi M, Manser AR, Uhrberg M, Verbeek W, Koschmieder S, Brümmendorf TH, Brossart P, Heine A, Wolf D. Schönberg K, et al. Among authors: brummendorf th. Cancer Res. 2015 Jun 1;75(11):2187-99. doi: 10.1158/0008-5472.CAN-14-3198. Epub 2015 Apr 1. Cancer Res. 2015. PMID: 25832652
Dissecting Genomic Aberrations in Myeloproliferative Neoplasms by Multiplex-PCR and Next Generation Sequencing.
Kirschner MM, Schemionek M, Schubert C, Chatain N, Sontag S, Isfort S, Ortiz-Brüchle N, Schmitt K, Krüger L, Zerres K, Zenke M, Brümmendorf TH, Koschmieder S. Kirschner MM, et al. Among authors: brummendorf th. PLoS One. 2015 Apr 20;10(4):e0123476. doi: 10.1371/journal.pone.0123476. eCollection 2015. PLoS One. 2015. PMID: 25894969 Free PMC article.
Identification of the Adapter Molecule MTSS1 as a Potential Oncogene-Specific Tumor Suppressor in Acute Myeloid Leukemia.
Schemionek M, Kharabi Masouleh B, Klaile Y, Krug U, Hebestreit K, Schubert C, Dugas M, Büchner T, Wörmann B, Hiddemann W, Berdel WE, Brümmendorf TH, Müller-Tidow C, Koschmieder S. Schemionek M, et al. Among authors: brummendorf th. PLoS One. 2015 May 21;10(5):e0125783. doi: 10.1371/journal.pone.0125783. eCollection 2015. PLoS One. 2015. PMID: 25996952 Free PMC article.
Telomere length at diagnosis of chronic phase chronic myeloid leukemia (CML-CP) identifies a subgroup with favourable prognostic parameters and molecular response according to the ELN criteria after 12 months of treatment with nilotinib.
Wenn K, Tomala L, Wilop S, Vankann L, Hasenbank C, Frank O, Hochhaus A, Giles FJ, Lange T, Müller MC, Koschmieder S, Beier F, Ziegler P, Brümmendorf TH. Wenn K, et al. Among authors: brummendorf th. Leukemia. 2015 Dec;29(12):2402-4. doi: 10.1038/leu.2015.245. Epub 2015 Sep 15. Leukemia. 2015. PMID: 26369986 No abstract available.
362 results